Jun 2026 (Q2 FY26) — Aug 6, 2026
Guardian Pharmacy Services Q2 FY26 — Strong EBITDA Growth Amid IRA Headwinds
Read the full callGuardian Pharmacy Services (GRDN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Guardian Pharmacy Services earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 352 | +2.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.9 | +2.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 21.9 | +142.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$40.14 +1.70% · +$0.67
Performance +60.9% 1Y
1Y: $24.95 on 17 Oct 2025 → $40.14. High $48 (15 Sept 2026), low $24.95 (17 Oct 2025).
- Previous close
- $39.47
- 52-week range
- $25.89 – $48
- One year
- +55.04%
Overview
- Symbol
- GRDN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Guardian Pharmacy Services earnings calls (GRDN)
Financials
What the filings say
Net profit, year on year: +142% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 339 | 329 | 344 | 377 | 398 | 337 | 352 |
| Operating profit | -105 | 17 | 13 | 13 | 16 | 31 | 18 | 21 |
| Operating margin | −33.3% | 5.0% | 4.0% | 3.6% | 4.3% | 7.7% | 5.3% | 5.9% |
| Other income | -1 | -1 | 0 | 0 | 0 | 0 | 1 | 9 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -106 | 16 | 13 | 13 | 17 | 31 | 18 | 30 |
| Tax rate | −0.2% | 27.0% | 29.3% | 29.9% | 42.3% | 31.6% | 26.0% | 25.8% |
| Net profit | -122 | 12 | 9 | 9 | 10 | 21 | 13 | 22 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Reserves | 17 | 66 |
| Total liabilities | 171 | 195 |
| Fixed assets | 50 | 56 |
| Total assets | 321 | 413 |
| Line item | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash from operations | 58 | 100 |
| Cash from investing | -30 | -32 |
| Cash from financing | -24 | -7 |
| Net cash flow | 4 | 61 |
| Capital expenditure | -15 | -13 |
| Free cash flow | 43 | 87 |
Insider filings
45 filings between Dec 3, 2025 and Sep 27, 2026.
Open market
decisions to buy or sellPurchases
$99.8K
1 purchase by 1 insider
Sales
$419.26M
10 sales by 9 insiders
Compensation
not trading decisions- 5
- Award — granted as compensation
- 27
- Option exercise — converted options into shares
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BINDLEY WILLIAM E | — | $105.99M | Mar 20, 2026 |
| Salentine Thomas J Jr | — | $105.99M | Mar 20, 2026 |
| Bindley Capital Partners I, LLC | — | $105.99M | Mar 20, 2026 |
| Ackerman John | — | $32.75M | Mar 20, 2026 |
| Pharmacy Investors, LLC | — | $24.57M | Mar 20, 2026 |
| Burke Fred | — | $19.93M | Mar 20, 2026 |
| Forbes Kendall | — | $10.29M | Mar 20, 2026 |
| Cardinal Equity Fund, L.P. | — | $8.18M | Mar 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 27, 2026 | Burke Fred See Remarks | Option exercise | 1,298,825 | — |
| Sep 27, 2026 | Tuch Jeffrey See Remarks | Option exercise | 55,578 | — |
| Sep 27, 2026 | Forbes Kendall Insider | Option exercise | 608,570 | — |
| Sep 27, 2026 | BINDLEY WILLIAM E Director | Option exercise | 6,100,175 | — |
| Sep 27, 2026 | Morris David K See Remarks | Option exercise | 641,870 | — |
| Sep 27, 2026 | Crisafulli Chris See Remarks | Option exercise | 18,931 | — |
| Sep 27, 2026 | Eakins Richard Senior Vice President, Sales | Option exercise | 36,052 | — |
| Sep 27, 2026 | Bindley Capital Partners I, LLC 10% owner | Option exercise | 6,100,175 | — |
| Sep 27, 2026 | Towns Douglas See Remarks | Option exercise | 23,450 | — |
| Sep 27, 2026 | Cardinal Equity Fund, L.P. Insider | Option exercise | 471,057 | — |
| Sep 27, 2026 | Salentine Thomas J Jr Director | Option exercise | 6,100,175 | — |
| Sep 27, 2026 | Martin David Norman See Remarks | Option exercise | 39,865 | — |
| Sep 27, 2026 | Pharmacy Investors, LLC Insider | Option exercise | 1,413,939 | — |
| Sep 27, 2026 | Mudd William Franklin See Remarks | Option exercise | 38,282 | — |
| Sep 27, 2026 | Weir Robert See Remarks | Option exercise | 23,450 | — |
| Sep 27, 2026 | Ackerman John Director | Option exercise | 471,057 | — |
| Sep 27, 2026 | Ackerman John Director | Option exercise | 1,413,939 | — |
| May 5, 2026 | Patchett Mary Sue Director | Award | 4,028 | $0 |
| May 5, 2026 | LEWIS RANDALL J Director | Award | 4,028 | $0 |
| May 5, 2026 | COSLER STEVEN D Director | Award | 4,028 | $0 |
| Mar 28, 2026 | BINDLEY WILLIAM E Director | Option exercise | 6,100,175 | — |
| Mar 28, 2026 | Burke Fred See Remarks | Option exercise | 1,298,826 | — |
| Mar 28, 2026 | Ackerman John Director | Option exercise | 1,413,939 | — |
| Mar 28, 2026 | Ackerman John Director | Option exercise | 471,057 | — |
| Mar 28, 2026 | Bindley Capital Partners I, LLC 10% owner | Option exercise | 6,100,175 | — |
| Mar 28, 2026 | Morris David K See Remarks | Option exercise | 641,869 | — |
| Mar 28, 2026 | Forbes Kendall See Remarks | Option exercise | 608,570 | — |
| Mar 28, 2026 | Salentine Thomas J Jr Director | Option exercise | 6,100,175 | — |
| Mar 28, 2026 | Cardinal Equity Fund, L.P. Insider | Option exercise | 471,057 | — |
| Mar 28, 2026 | Pharmacy Investors, LLC Insider | Option exercise | 1,413,939 | — |
| Mar 20, 2026 | BINDLEY WILLIAM E Director | Sale | 3,570,677 | $105.99M |
| Mar 20, 2026 | Ackerman John Director | Sale | 827,636 | $24.57M |
| Mar 20, 2026 | Forbes Kendall See Remarks | Sale | 346,672 | $10.29M |
| Mar 20, 2026 | Morris David K See Remarks | Sale | 187,855 | $5.58M |
| Mar 20, 2026 | Pharmacy Investors, LLC Insider | Sale | 827,636 | $24.57M |
| Mar 20, 2026 | Burke Fred See Remarks | Sale | 671,432 | $19.93M |
| Mar 20, 2026 | Cardinal Equity Fund, L.P. Insider | Sale | 275,728 | $8.18M |
| Mar 20, 2026 | Salentine Thomas J Jr Director | Sale | 3,570,677 | $105.99M |
| Mar 20, 2026 | Bindley Capital Partners I, LLC 10% owner | Sale | 3,570,677 | $105.99M |
| Mar 20, 2026 | Ackerman John Director | Sale | 275,728 | $8.18M |
| Mar 1, 2026 | Morris David K See Remarks | Award | 8,952 | $0 |
| Mar 1, 2026 | Forbes Kendall See Remarks | Award | 8,952 | $0 |
| Dec 4, 2025 | Burke Fred See Remarks | Gift | 200,000 | $0 |
| Dec 4, 2025 | Forbes Kendall See Remarks | Gift | 21,500 | $0 |
| Dec 3, 2025 | COSLER STEVEN D Director | Purchase | 3,370 | $99.8K |
| Sep 27, 2025 | Forbes Kendall See Remarks | Option exercise | 608,570 | — |
| Sep 27, 2025 | Cardinal Equity Fund, L.P. Insider | Option exercise | 471,057 | — |
| Sep 27, 2025 | Pharmacy Investors, LLC Insider | Option exercise | 1,413,940 | — |
| Sep 27, 2025 | Bindley Capital Partners I, LLC 10% owner | Option exercise | 6,100,176 | — |
| Sep 27, 2025 | Salentine Thomas J Jr Director | Option exercise | 6,100,176 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Guardian Pharmacy Services, Inc.
Free account. Everything above stays public.
Write why you follow Guardian Pharmacy Services, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading